The Study of Apoptosis Induced by Allicin in HT-9/HL-60 and its Transfection Cell | Scientific.Net (original) (raw)
[1] Ghosh S, Bandyopadhyay S, Pal S, Das B, Bhattacharya DK, and Mandal C. Increased interferon gamma production by peripheral blood mononuclear cells in response to stimulation of over expressed diseasespecific 9-O-acetylated sialoglycoconjugates in children suffering from acute lymphoblastic leukemia. British J Haematol, vol. 128, no. 1, pp.35-41, January (2005).
DOI: 10.1111/j.1365-2141.2004.05256.x
[2] Pal S, Ghosh S, Bandyopadhyay S, Mandal C, Bandhyopadhyay S, Bhattacharya DK, et al. Differential expression of 9-O-acetylated sialoglycoconjugates on leukemic blasts: a potential tool for long-term monitoring of children with acute lymphoblastic leukaemia. Inter J Cancer, vol. 111, no. 2, pp.270-277, August (2004).
DOI: 10.1002/ijc.20246
[3] Chitra M, Chatterjee M, Sinha D, Investigation of 9-O-Acetylated sialogly- cocongugates in childhood acute lymphoblastic leukaemia. British J Haematol, vol. 110, no. 4, pp.801-812, September (2000).
DOI: 10.1046/j.1365-2141.2000.02105.x
[4] Sinha D, Mandal C, Bhattacharya DK, Identification of 9-O acetyl sialoglycoconjugates (9-OAcSGs) as biomarkers in childhood acute lymphoblastic leukemia using a lectin, AchatininH, as a probe, Leukemia, vol. 13, no. 1, pp.119-125, January (1999).
[5] Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood, vol. 107, no. 9, pp.3481-3485, May (2006).
DOI: 10.1182/blood-2005-09-3724
[6] Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood, vol. 108, no. 10, pp.3280-3288, November (2006).
DOI: 10.1182/blood-2006-04-014324
[7] Drach J, Zhao S, Drach D, Korbling M, Engel H, Andreeff M. Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis. Leuk Lymphoma, vol. 16, no. 5, pp.419-424, February (1995).
DOI: 10.3109/10428199509054428
[8] Malayeri R, Filipits M, Suchomel RW, Zochbauer S, Lechner K, Pirker R. Multidrug resistance in leukemias and its reversal. Leuk Lymphoma, vol. 23, no. 5, pp.451-458, November (1996).
DOI: 10.3109/10428199609054853
[9] Pui CH, Robison LL, Look AT, Acute lymphoblastic leukaemia. Lancet, vol. 371, no. 9617, pp.1030-1043, March (2008).
DOI: 10.1016/s0140-6736(08)60457-2
[10] Liu XL, Tee H W, Go ML. Functionalized chalcones as selective inhibitors of P-glycoprotein and breast cancer resistance protein [J]. Bioorg Med Chem, vol. 16, no. 1, pp.171-180, January (2008).
DOI: 10.1016/j.bmc.2007.10.006
[11] Gao P , Zhou G Y, Lei D P , Zhang XF, Li L, Xu JW, et al. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells. Cytotherapy, vol. 9, no. 8, pp.795-801, October (2007).
DOI: 10.1080/14653240701656087
[12] Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther, vol. 11, no. 4, pp.508-522, April (2005).
DOI: 10.1016/j.ymthe.2004.11.016
[13] El-Khoury V, Breuzard G, Fourré N , Dufer J. The histone deacetylase inhibitor trichostatin A downregulates human MDR1 (ABCB1) gene expression by a transcription-dependent mechanism in a drug-resistant small cell lung carcinoma cell line model. Br J Cancer, vol. 97, no. 4, pp, 562-573, August (2007).
[14] Kaszubiak A, Holm P S, Lage H. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes. Int J Oncol, vol. 31, no. 2, pp.419-430, August (2007).
DOI: 10.3892/ijo.31.2.419
[15] Berezhna S Y, Supekova L, Supek F, Schultz PG, Deniz AA. siRNA in human cells selectively localizes to target RNA sites. Proc Natl Acad Sci U S A. vol. 103, no. 20, pp.7682-7687, May (2006).
[16] Jaskiewicz L, Filipowicz W. Role of Dicer in posttranscriptional RNA silencing. Curr Top Microbiol Immunol, vol. 320, pp.77-97, (2008).
DOI: 10.1007/978-3-540-75157-1_4
[17] Shao SL, Sun YY, Li XY, Zhang WW, Fu B, Yun DZ, et al. The reversion effect of the RNAi-silencing mdr1 gene on multidrug resistance of the leukemia cell HT9. Cell biology intemational, vol. 32, no. 8, pp.893-898, August (2008).
DOI: 10.1016/j.cellbi.2008.03.021
[18] Shao SL, Zhang WW, Li XY, Zhang ZZ, Yun DZ, Fu B, et al. Reversal of MDR1 gene-dependent multidrug resistance in HL60/HT9 cells using short hairpin RNA expression vectors. Cancer Biother Radiopham, vol. 25, no. 2, pp.171-177, April (2010).
[19] Gottesman MM, Fojo T, Bates S E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer, vol. 2, no. 1, pp.48-58, January (2002).
DOI: 10.1038/nrc706
[20] Xu, D, Ye D, Fisher M, and Juliano RL. Selective inhibition of P-glycoprotein expression in multidrug- resistant tumor cells by a designed transcriptional regulator. J Pharmacol Exp Ther, vol. 302, no. 3, pp.963-971, September (2002).
[21] Mechetner EB and Roninson IB. Efficient inhibition of P-glycoprotein mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA, vol. 89, no. 13, pp.5824-5828, July (1992).
[22] Boutros M, Ahringer J, The art and design of genetic screens: RNA interference. Nat Rev Genet, vol. 9, no. 7, pp.554-566, July (2008).
DOI: 10.1038/nrg2364
[23] Castanotto D, Rossi JJ, The promises and pitfalls of RNA interference-based therapeutics. Nature, vol. 457, no. 7228, pp.426-433, January (2009).
DOI: 10.1038/nature07758
[24] Li Y, Yang L, Cui JT, Li WM, Guo RF, Lu YY. Construction of cDNA representational difference analysis based on two cDNA libraries and identification of garlic inducible expression genes in human gastric cancer cells. World J Gastroenterol, vol. 8, no. 2, pp.208-212, April (2002).
[25] Arditti FD, Rabinkov A, Miron T, Reisner Y, Berrebi A, Wilchek M, et al. Apoptotic killing of B-chronic lymphocytic leukemia tumor cells by allicin generated in situ using a rituximab-alliinase conjugate. Mol Cancer Ther, vol. 4, no. 2, pp.325-331, February (2005).
DOI: 10.1158/1535-7163.325.4.2
[26] Iovino CS, Camacho LH. Acute myeloid leukemia: a classification and treatment update. Clin J Oncol Nurs, vol. 7, no. 5, pp.535-540, September-October (2003).
[27] Cao TM, Coutre SE. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H). Hematology, vol. 8, no. 1, pp.1-6, February (2003).